Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21655052 | 0.85 | DRD2 (0.47) | DRD2HTR2AHRH1DRD4DRD3 | |
| SCHEMBL18715752 | 0.82 | DRD2 (0.36) | DRD2HTR2AHRH1DRD4DRD3 | |
| SCHEMBL902615 | 0.78 | SLC6A3 (0.44) | DRD2HTR2AHRH1SLC6A3ADORA2A | |
| Hydrochloric Acid SCHEMBL6090064 | 0.76 | SLC6A3 (0.43) | DRD2HTR2AHRH1SLC6A3ADORA2A | |
| SCHEMBL24415625 | 0.76 | HPGD (0.43) | DRD2HTR2AHRH1SLC6A3ALDH1A1 | |
| SCHEMBL7179725 | 0.75 | SLC6A3 (0.42) | DRD2HTR2AHRH1SLC6A3ADORA2A | |
| SCHEMBL7175958 | 0.75 | CCR4 (0.43) | DRD2HTR2AHRH1SLC6A3ADORA2A | |
| SCHEMBL7187137 | 0.72 | SLC6A3 (0.40) | DRD2HTR2AHRH1SLC6A3ADORA2A | |
| SCHEMBL2819208 | 0.72 | DRD2 (0.45) | DRD2HTR2AHRH1SLC6A3ADORA2A | |
| SCHEMBL2819185 | 0.71 | SLC6A3 (0.47) | DRD2HTR2AHRH1SLC6A3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3696171-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3689353-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3112355-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-5583232-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-10 | — | — | US | disclosed |
| US-5583233-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-10 | — | — | US | disclosed |
| US-5580984-A | 1-OXA-3-AZA-2-BORINE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| US-5565418-A | PREPARING CARBAMATE INTERMEDIATES BY REACTING SUBSTITUTED HYDROXYDIAMINE COMPOUND WITH ONE AMINE PROTECTED WITH ACTIVATED ACYLATING AGENT, DEPROTECTING | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0674513-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5552558-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0727419-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | disclosed |
| US-5541206-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5539122-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1994014436-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | DRD2 4309/4885HTR2A 3656/4885HRH1 1931/4885 |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | DRD2 4039/4885HTR2A 3517/4885HRH1 2399/4885 |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | DRD2 4309/4885HTR2A 3656/4885HRH1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.